bluebird bio Inc (NASDAQ:BLUE) insider Philip D. Gregory sold 850 shares of the business’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $101.20, for a total value of $86,020.00. Following the transaction, the insider now directly owns 30,692 shares of the company’s stock, valued at $3,106,030.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Shares of NASDAQ BLUE opened at $101.08 on Thursday. The company has a current ratio of 8.02, a quick ratio of 8.02 and a debt-to-equity ratio of 0.11. bluebird bio Inc has a twelve month low of $87.49 and a twelve month high of $163.43. The stock has a 50 day moving average of $116.08 and a two-hundred day moving average of $132.16. The stock has a market cap of $5.59 billion, a P/E ratio of -9.46 and a beta of 2.28.
bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($3.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($3.04) by ($0.51). bluebird bio had a negative net margin of 1,158.04% and a negative return on equity of 35.90%. The firm had revenue of $13.30 million during the quarter, compared to analysts’ expectations of $13.13 million. During the same quarter in the prior year, the firm posted ($2.91) EPS. bluebird bio’s quarterly revenue was up 68.4% compared to the same quarter last year. As a group, research analysts predict that bluebird bio Inc will post -13.22 earnings per share for the current year.
A number of equities analysts have recently commented on BLUE shares. Morgan Stanley lowered their price objective on bluebird bio from $143.00 to $136.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 6th. BMO Capital Markets lowered their price objective on bluebird bio from $191.00 to $163.00 and set an “outperform” rating for the company in a research report on Monday, June 17th. ValuEngine raised bluebird bio from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Wedbush downgraded bluebird bio from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $166.00 to $131.00 in a research report on Wednesday, May 15th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $195.00 price target on shares of bluebird bio in a report on Thursday, June 13th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating, ten have given a buy rating and two have given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $154.13.
bluebird bio Company Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.
Featured Article: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.